Equibles does not estimate personal net worth.
Get an email with a short summary when Lisata Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get LSTA alertsJosh Lehrer is recorded as COO at Lisata Therapeutics, Inc. (LSTA) since September 17, 2026. The newest filing on record that lists Josh Lehrer as COO at Lisata Therapeutics, Inc. (LSTA) is dated October 19, 2026. Lisata Therapeutics, Inc. reported in an 8-K filed September 17, 2026 that Josh Lehrer was appointed newly appointed Chief Operating Officer and President of Lisata Therapeutics and Chief Executive Officer of Marea. Josh Lehrer has spoken on 1 investor event across 1 company, most recently for Lisata Therapeutics, Inc. on November 10, 2026. Lisata Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Lisata Therapeutics, Inc. includes David J. Mazzo (CEO and Board Member), David J. Mazzo, Ph.D. (CEO), Gregory Brown (Chairman) and 7 others.
“"This transaction provides the combined company with the resources to advance our two clinical stage drug candidates through pivotal milestones, including MAR001 topline Phase 2b data in severe hypertriglyceridemia and MAR002 Phase 2 proof of concept data in patients with acromegaly next year, as well as initiation of Phase 3 registrational studies for both programs," said Dr. Josh Lehrer, newly appointed Chief Operating Officer and President of Lisata Therapeutics and Chief Executive Officer of Marea.”
“So, we're not even completely through this reverse merger, and we're in the fortunate position of having two molecules that have initial clinical validation and look like drugs, both first in class.”
2026-09-17–present
Last confirmed October 19, 2026
Biotechnology · Healthcare
COO
2026-09-17–present
